ArticleEuropean journal of pediatrics2008
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia.
Article in European journal of pediatrics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Early biomarkers as predictors for bronchopulmonary dysplasia in preterm infants: a systematic review.European journal of pediatrics · 2014Pooled it
- Comparable effect of conventional ventilation versus early high-frequency oscillation on serum CC16 and IL-6 levels in preterm neonates.Journal of perinatology : official journal of the California Perinatal Association · 2011Trial
- From respiratory infections to environmental exposures: CC16 is a key modulator of airway homeostasis.Frontiers in medicine · 2026Review
- The role of CC16 in the associations of preterm birth with lung function and asthma in adult life.The Journal of allergy and clinical immunology · 2026Article
- Club cell secretory protein (CC16) polymorphisms in preterm neonates with respiratory distress syndrome and bronchopulmonary dysplasia.European journal of pediatrics · 2025Article
- Reinitiating lung development: a novel approach in the management of bronchopulmonary dysplasia.Respiratory research · 2024Review
- Early prediction of bronchopulmonary dysplasia: can noninvasive monitoring methods be essential?ERJ open research · 2023Review
- Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?Frontiers in pediatrics · 2022Review
- Club Cell Secreted Protein CC16: Potential Applications in Prognosis and Therapy for Pulmonary Diseases.Journal of clinical medicine · 2020Review
- Clara Cell Protein Expression in Mechanically Ventilated Term and Preterm Infants with Respiratory Distress Syndrome and at Risk of Bronchopulmonary Dysplasia: A Pilot Study.Canadian respiratory journal · 2017Article
- Biomarkers in Pediatric ARDS: Future Directions.Frontiers in pediatrics · 2016Review
- Biomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary Dysplasia.Clinics in perinatology · 2015Review
- Correlation of serum KL-6 and CC16 levels with neurodevelopmental outcome in premature infants at 12 months corrected age.Scientific reports · 2015Article
- Drug therapy for the prevention and treatment of bronchopulmonary dysplasia.Frontiers in pharmacology · 2015Review
- A comparison of KL-6 and Clara cell protein as markers for predicting bronchopulmonary dysplasia in preterm infants.Disease markers · 2014Article
- Neonatal hyperoxic exposure persistently alters lung secretoglobins and annexin A1.BioMed research international · 2013Article
- Genome-wide transcriptional profiling reveals connective tissue mast cell accumulation in bronchopulmonary dysplasia.American journal of respiratory and critical care medicine · 2012Article
- Clara cell protein in bronchoalveolar lavage fluid: a predictor of ventilator-associated pneumonia?Critical care (London, England) · 2011Article
- Clara cell secretory protein and bronchopulmonary dysplasia in prematurely born infants.European journal of pediatrics · 2008Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Clara cell protein (CC16) is an anti-inflammatory protein and a biomarker of pulmonary epithelial cells and alveolocapillary membrane injury in adults. We investigated whether low cord blood concentrations of CC16 are associated with the development of respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) in preterm infants and the relationship between CC16 and its pro-inflammatory counterpart, the secretory phospholipase A(2) (sPLA(2)) enzyme. CC16 concentration, sPLA(2) activity and IL-6 concentration were measured in cord blood plasma from 79 preterm infants (25 controls, 37 infants who developed RDS and 17 infants who developed BPD). After adjustment for gestational age and Apgar score at 5 min, the CC16 concentration was lower in BPD infants than in preterm controls (p<0.01). sPLA(2) activity was similar in all groups and the IL-6 concentrations were increased in both RDS and BPD infants (p<0.01 and p<0.05, respectively, vs. controls). We conclude that low cord blood CC16 concentrations in preterm infants independently predict the development of BPD. Low CC16 levels may reflect early lung injury, which contributes to the severity of RDS and progress towards BPD. Future studies are needed to assess whether the early administration of recombinant human CC16 in preterm infants with low cord blood CC16 prevents the development of BPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.